These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 1742754)

  • 21. The pragmatic use of apomorphine at the end of life.
    Dewhurst F; Lee M; Wood B
    Palliat Med; 2009 Dec; 23(8):777-9. PubMed ID: 19837701
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
    Deleu D; Hanssens Y; Northway MG
    Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Continuous subcutaneous apomorphine monotherapy in Parkinson's disease.
    Papuć E; Trzciniecka O; Rejdak K
    Ann Agric Environ Med; 2019 Mar; 26(1):133-137. PubMed ID: 30922043
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Timing of yawns induced by a small dose of apomorphine and its alteration by naloxone.
    Szechtman H
    Prog Neuropsychopharmacol Biol Psychiatry; 1984; 8(4-6):743-6. PubMed ID: 6531446
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of pretreatment with naloxone on behaviours induced by a small dose of apomorphine.
    Szechtman H
    Pharmacol Biochem Behav; 1986 Jun; 24(6):1779-83. PubMed ID: 3737643
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Apomorphine (Apokyn) for advanced Parkinson's Disease.
    Med Lett Drugs Ther; 2005 Jan; 47(1200):7-8. PubMed ID: 15647705
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson's disease patients: pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study.
    Zijlmans JC; Debilly B; Rascol O; Lees AJ; Durif F
    Mov Disord; 2004 Sep; 19(9):1006-1011. PubMed ID: 15372589
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Apomorphine in off state--clinical experience].
    Rudzińska M; Szczudlik A
    Neurol Neurochir Pol; 2007; 41(2 Suppl 1):S40-8. PubMed ID: 17941458
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Apomorphine test for dopaminergic responsiveness: a dose assessment study.
    Bonuccelli U; Piccini P; Del Dotto P; Rossi G; Corsini GU; Muratorio A
    Mov Disord; 1993 Apr; 8(2):158-64. PubMed ID: 8474482
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Apomorphine: clinical studies on erectile impotence and yawning.
    Lal S; Tesfaye Y; Thavundayil JX; Thompson TR; Kiely ME; Nair NP; Grassino A; Dubrovsky B
    Prog Neuropsychopharmacol Biol Psychiatry; 1989; 13(3-4):329-39. PubMed ID: 2748870
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of apomorphine-induced yawning and penile erection by neurotensin.
    Nouel D; Costentin J
    Peptides; 1991; 12(4):755-9. PubMed ID: 1788138
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intermittent subcutaneous apomorphine injection treatment for parkinsonian motor oscillations.
    Kempster PA; Iansek R; Larmour I
    Aust N Z J Med; 1991 Jun; 21(3):314-8. PubMed ID: 1953509
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of central dopaminergic stimulation by apomorphine on speech in Parkinson's disease.
    Kompoliti K; Wang QE; Goetz CG; Leurgans S; Raman R
    Neurology; 2000 Jan; 54(2):458-62. PubMed ID: 10668714
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Other formulations and future considerations for apomorphine for subcutaneous injection therapy.
    Koller W; Stacy M
    Neurology; 2004 Mar; 62(6 Suppl 4):S22-6. PubMed ID: 15037668
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Continuous perioperative apomorphine in deep brain stimulation surgery for Parkinson's disease.
    Slotty PJ; Wille C; Kinfe TM; Vesper J
    Br J Neurosurg; 2014 Jun; 28(3):378-82. PubMed ID: 24073755
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Apomorphine increases blood glucose concentrations in Parkinson's disease.
    Tison F; Fouillet N; Henry P
    Clin Neuropharmacol; 1994 Feb; 17(1):92-5. PubMed ID: 8149364
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial.
    Katzenschlager R; Poewe W; Rascol O; Trenkwalder C; Deuschl G; Chaudhuri KR; Henriksen T; van Laar T; Spivey K; Vel S; Staines H; Lees A
    Lancet Neurol; 2018 Sep; 17(9):749-759. PubMed ID: 30055903
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up.
    Pietz K; Hagell P; Odin P
    J Neurol Neurosurg Psychiatry; 1998 Nov; 65(5):709-16. PubMed ID: 9810943
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Subcutaneous apomorphine in the treatment of Parkinson's disease].
    Linazasoro G
    Neurologia; 1994 Jan; 9(1):1-3. PubMed ID: 8161461
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiovascular reflexes in Parkinson's disease: effect of domperidone and apomorphine.
    Merello M; Pirtosek Z; Bishop S; Lees AJ
    Clin Auton Res; 1992 Aug; 2(4):215-9. PubMed ID: 1392539
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.